Given that PD-L1 expression may predict the response to immunotherapy in endometrial cancer, our primary objective was to compare the clinicopathologic characteristics of PD-L1–positive tumors with those of PD-L1–negative tumors. This evidence concerns the gene CD274 and endometrial cancer.